drugset
drugset / Trial / NCT00761696

A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies

NCT00761696 ↗

Phase 1 Completed 94 enrolled Infinity Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The primary objectives of the study are: * To determine the safety and the maximum tolerated dose (MTD) of IPI-926 * To examine the pharmacokinetic parameters of IPI-926 and its characterized major metabolite(s) * To recommend a dose and schedule of IPI-926 for subsequent studies

Timeline

Start
2008-09
Primary completion
2012-04
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Patidegib Small molecule — Oral

Indications

neoplasm